Mexico vs Papua New Guinea: Average cost of multi drug-resistant tuberculosis treatment
Mexico
1,000 constant 2022 US$
in 2024
Papua New Guinea
953 constant 2022 US$
in 2022
Mexico rank
48th
Papua New Guinea rank
51st
Average cost of multi drug-resistant tuberculosis treatment over time
- Mexico
- Papua New Guinea
How they compare
Mexico currently reports 1,000 constant 2022 US$ against 953 constant 2022 US$ in Papua New Guinea, a difference of 47 constant 2022 US$.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was Papua New Guinea ahead.
Mexico ranks 48th and Papua New Guinea ranks 51st of 92 countries.
Papua New Guinea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Mexico | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,022 constant 2022 US$ | 2,096 constant 2022 US$ | 1,074 constant 2022 US$ | Papua New Guinea |
| 2020s | 800.67 constant 2022 US$ | 871.67 constant 2022 US$ | 71 constant 2022 US$ | Papua New Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Mexico or Papua New Guinea?
- Mexico, at 1,000 constant 2022 US$ against 953 constant 2022 US$ in Papua New Guinea as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Mexico and Papua New Guinea?
- 47 constant 2022 US$, with Mexico ahead.
- How many years of comparable data are there for Mexico and Papua New Guinea?
- 5 years are reported by both, from 2017 to 2022.
- How do Mexico and Papua New Guinea rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Mexico ranks 48th and Papua New Guinea ranks 51st of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.